Your browser doesn't support javascript.
loading
Type I IFN system activation in newborns exposed to Ro/SSA and La/SSB autoantibodies in utero.
Hedlund, Malin; Thorlacius, Gudny Ella; Ivanchenko, Margarita; Ottosson, Vijole; Kyriakidis, Nikolaos; Lagnefeldt, Linda; Tingström, Joanna; Sirsjö, Allan; Bengtsson, Anders A; Aronsson, Emma; Gemzell-Danielsson, Kristina; Ronnblom, Lars; Bergman, Gunnar; Espinosa, Alexander; Sonesson, Sven-Erik; Eloranta, Maija-Leena; Wahren-Herlenius, Marie.
Afiliación
  • Hedlund M; Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Thorlacius GE; Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Ivanchenko M; Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Ottosson V; Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Kyriakidis N; Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Lagnefeldt L; Facultad de Ciencias de la Salud, Escuela de Medicina, Grupo de Investigación en Biotecnología Aplicada a Biomedicina (BIOMED), Universidad de Las Américas (UDLA), Quito, Ecuador.
  • Tingström J; Pediatric Cardiology Unit, Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Sirsjö A; Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Bengtsson AA; Cardiovascular Research Centre, School of Health and Medical Sciences, Örebro Univeristy, Örebro, Sweden.
  • Aronsson E; Division of Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden.
  • Gemzell-Danielsson K; Division of Obstetrics and Gynecology, Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Ronnblom L; Division of Obstetrics and Gynecology, Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Bergman G; Rheumatology, Department of Medical Sciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Espinosa A; Pediatric Cardiology Unit, Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Sonesson SE; Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Eloranta ML; Pediatric Cardiology Unit, Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Wahren-Herlenius M; Rheumatology, Department of Medical Sciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
RMD Open ; 6(1)2020 01.
Article en En | MEDLINE | ID: mdl-31958275
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Interferón Tipo I / Anticuerpos Antinucleares / Bloqueo Cardíaco Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Newborn / Pregnancy País/Región como asunto: Europa Idioma: En Revista: RMD Open Año: 2020 Tipo del documento: Article País de afiliación: Suecia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Interferón Tipo I / Anticuerpos Antinucleares / Bloqueo Cardíaco Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Newborn / Pregnancy País/Región como asunto: Europa Idioma: En Revista: RMD Open Año: 2020 Tipo del documento: Article País de afiliación: Suecia